USPTO Finds Claims Of Two Of Moderna’s mRNA Patents Unpatentable: What’s Next In The Vaccine Wars? Legal News and Analysis - ...

Scientists have made a major breakthrough in the accuracy and speed at which often deadly pathogen infections can be ...

In this week’s edition of the biotech bi-weekly, learn more about Thermo Fisher’s new system for automating complex sample ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.62, a high estimate of $8.00, ...

Hajun Kim, Taejoon Kwon, and Joo Hun Kang—from the Department of Biomedical Engineering at UNIST has unveiled a novel ...

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going ...

The launch of Denarase High Salt GMP-grade marks a significant milestone in c-LEcta’s commitment to providing innovative solutions for the biopharmaceutical industry. This engineered enzyme ...

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D ...

Union Health Minister announced that the tuberculosis elimination program is not expanded nationwide. He shared that RT-PCR ...

A team of scientists just discovered the longest organic molecules yet seen on Mars, the fourth planet from the Sun and and a ...

DNA is fundamental to the biology of all life on Earth, but how many of us actually know what it is or what it's made of?

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.